AZD-5423
Chemical compound / From Wikipedia, the free encyclopedia
AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca[1] and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.[2][3][4][5][6]
Quick Facts Identifiers, CAS Number ...
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.205.965 |
Chemical and physical data | |
Formula | C25H21F4N3O3 |
Molar mass | 487.455 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
It has completed a phase II clinical trial.[7]